Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / Exelixis, Inc.
2008 · Co-Development · $240M · Complete
Announcement Sentiment
75
Strongly positive
$195M upfront + $45M 2009 + up to $150M sales milestones + double-digit ex-US royalties; XL184 (cabozantinib) MET/VEGFR/RET, XL281 RAF kinase oncology
Key facts
- Announced Dec 08, 2008
- Deal value $240M
- Deal type Co-Development
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals